{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:19:56Z","timestamp":1775715596293,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1124\/dmd.117.078790","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T16:45:39Z","timestamp":1515775539000},"page":"346-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects"],"prefix":"10.1016","volume":"46","author":[{"given":"Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Niosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Tess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangwoo","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman F.","family":"El-Kattan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry M.","family":"Tremaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.078790_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1021\/j150560a005","article-title":"Application of the theory of diffusion-controlled reactions to enzyme kinetics","volume":"62","author":"Alberty","year":"1958","journal-title":"J Phys Chem"},{"key":"10.1124\/dmd.117.078790_bib2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1476-5381.1996.tb15292.x","article-title":"Endothelin receptors in human coronary artery and aorta","volume":"117","author":"Bacon","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.117.078790_bib3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/00912700222011300","article-title":"Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist","volume":"42","author":"Dingemanse","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078790_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.117.078790_bib5","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1007\/s11095-016-2024-z","article-title":"Projecting ADME behavior and drug-drug interactions in early discovery and development: application of the extended clearance classification system","volume":"33","author":"El-Kattan","year":"2016","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.117.078790_bib6","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078790_bib7","doi-asserted-by":"crossref","first-page":"e47662","DOI":"10.1371\/journal.pone.0047662","article-title":"Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells","volume":"7","author":"Gatfield","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/dmd.117.078790_bib8","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2967\/jnumed.116.177774","article-title":"In vivo imaging of human 11C-metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses","volume":"57","author":"Gormsen","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.117.078790_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00003088-198611060-00005","article-title":"Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship","volume":"11","author":"Holford","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.117.078790_bib10","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/jpet.106.119073","article-title":"Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP\/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity","volume":"321","author":"Leslie","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.078790_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10928-014-9357-1","article-title":"A \u201cmiddle-out\u201d approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling","volume":"41","author":"Li","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.117.078790_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/dmd.117.078808","article-title":"A study on pharmacokinetics of bosentan with systems modeling, part 2: prospectively predicting systemic and liver exposure in healthy subjects","volume":"46","author":"Li","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078790_bib13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1208\/s12248-016-9895-0","article-title":"Does the systemic plasma profile inform the liver profile? Analysis using a physiologically based pharmacokinetic model and individual compounds","volume":"18","author":"Li","year":"2016","journal-title":"AAPS J"},{"key":"10.1124\/dmd.117.078790_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.117.078790_bib15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kft176","article-title":"A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development","volume":"136","author":"Morgan","year":"2013","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.117.078790_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/dmd.109.028746","article-title":"Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin","volume":"38","author":"Quinney","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078790_bib17","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"issue":"Suppl 3","key":"10.1124\/dmd.117.078790_bib18","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1097\/00005344-199526003-00103","article-title":"Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139","volume":"26","author":"Russell","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/dmd.117.078790_bib19","unstructured":"Shen G, Yao M, Fura A, Zhu M (2009) In vitro metabolite identification and cytochrome P450 reaction phenotyping of bosentan, a dual endothelin receptor antagonist, in Proceedings of the American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 2009 Nov 9\u201311; Los Angeles, CA. American Association of Pharmaceutical Scientists, Arlington, VA."},{"key":"10.1124\/dmd.117.078790_bib20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.nucmedbio.2012.01.008","article-title":"Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3","volume":"39","author":"Shimizu","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1124\/dmd.117.078790_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4149\/gpb_2015050","article-title":"Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters","volume":"35","author":"Srinivas","year":"2016","journal-title":"Gen Physiol Biophys"},{"key":"10.1124\/dmd.117.078790_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/dmd.117.075481","article-title":"Quantitative prediction of CYP3A4 induction: impact of measured, free, and intracellular perpetrator concentrations from human hepatocyte induction studies on drug-drug interaction predictions","volume":"45","author":"Sun","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078790_bib23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078790_bib24","unstructured":"U.S. Food and Drug Administration (2001) Clinical Pharmacology and Biopharmaceutics Review: NDA-21-290. U.S. Food and Drug Administration Center for Drug Evaluation and Research, Bethesda, MD."},{"key":"10.1124\/dmd.117.078790_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0014-2999(02)02075-7","article-title":"Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor","volume":"450","author":"van Giersbergen","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.117.078790_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2125.2002.01608.x","article-title":"Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole","volume":"53","author":"van Giersbergen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078790_bib27","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1124\/dmd.112.050583","article-title":"Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin","volume":"41","author":"Varma","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078790_bib28","doi-asserted-by":"crossref","unstructured":"Volz AK, Krause A, Haefeli WE, Dingemanse J, Lehr T (2017) Target-mediated drug disposition pharmacokinetic-pharmacodynamic model of bosentan and endothelin-1. Clin Pharmacokinet 56:1499\u20131511.","DOI":"10.1007\/s40262-017-0534-4"},{"key":"10.1124\/dmd.117.078790_bib29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/00912709922008380","article-title":"Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078790_bib30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0090-9556(24)15230-0","article-title":"Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects","volume":"27","author":"Weber","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078790_bib31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/00912709922008344","article-title":"Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078790_bib32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0009-9236(96)90127-7","article-title":"Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects","volume":"60","author":"Weber","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.078790_bib33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects","volume":"48","author":"Wrishko","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078790_bib34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.117.078790_bib35","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s11095-017-2168-5","article-title":"A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions","volume":"34","author":"Yoshikado","year":"2017","journal-title":"Pharm Res"}],"updated-by":[{"DOI":"10.1124\/dmd.117.078790err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000}},{"DOI":"10.1124\/dmd.117.078790err2","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000}}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.078790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:34:17Z","timestamp":1739903657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624054801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0090955624054801"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.078790","relation":{"erratum":[{"id-type":"doi","id":"10.1124\/dmd.117.078790err","asserted-by":"object"},{"id-type":"doi","id":"10.1124\/dmd.117.078790err2","asserted-by":"object"}]},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.078790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}